期刊文献+

SIRT1在宫颈癌细胞耐药中的作用及其机制研究 被引量:3

Role of SIRT1 in Drug Resistance of Cervical Cancer Cells
原文传递
导出
摘要 目的:探讨沉默交配型信息调节因子2同源蛋白1(silent mating type information regulation 2 homology 1,SIRT1)在宫颈癌化疗耐药中的作用及其机制。方法:体外培养人宫颈癌Hela细胞系和宫颈癌Hela/MMC耐药细胞亚系,western blotting检测MMC对Hela和Hela/MMC细胞内SIRT1蛋白表达的影响;MTT法检测MMC及Nicotinamide对Hela和Hela/MMC细胞增殖的影响;Annexin V-PI试验检测Hela/MMC细胞凋亡的亡的情况;RT-PCR方法检测耐药相关蛋白P-gp的mRNA表达情况。结果:正常情况下,Hela/MMC细胞中SIRT1的表达显著高于Hela细胞(P<0.05),MMC处理的Hela/MMC细胞中SIRT1的表达显著高于未经MMC处理(P<0.05)。Nicotinamide对Hela和Hela/MMC细胞具有相似的生长抑制作用,Nicotinamide可使MMC诱导的Hela/MMC细胞凋亡增加,同时降低细胞内P-gp的mRNA表达(P<0.05)。结论:SIRT1表达下调能显著减轻Hela/MMC细胞对MMC的耐药性,其作用可能与P-gp有关。 Objective: To discuss the role and mechanism of silent mating type information regulation 2 homology 1 (SIRT1) in cervical cancer drug resistance. Methods: Human cervical cancer Hela cell lines and cervical cancer Hela/MMC drug-resistant cell sublines were cultivated in vitro. The effects of MMC on SIRT1 protein expression was detected by Western blotting; MTT assay was used to detect the proliferative effect of Nicotinamide and MMC on Hela and Hela/MMC cells. Apoptotic cells were detected with Annexin V staining; mRNA of drug resistant-associated protein P-gp was measured by RT-PCR. Results: The expression of SIRT1 protein in Hela/MMC was significantly higher than that in Hela cells normally (P〈0.05) and the expression of SIRT1 protein in Hela/MMC MMC-treatment group was significantly higher than that in control (P〈0.05); SIRT1 inhibitors Nicotinamide exhibited the similar growth-inhibitory effects on Hela and Hela/MMC, which can induce the increase of Hela/MMC cell apoptosis and also reduce the mRNA level of P-gp (P〈0.05). Conclusion: The downregulation of SIRT1 can significantly mitigate MMC- resistance of MMC-Hela, which may be achieved by regulated P-gp expression.
出处 《现代生物医学进展》 CAS 2013年第24期4654-4657,共4页 Progress in Modern Biomedicine
关键词 SIRT1 烟酰胺 宫颈癌 耐药 SIRT1 Nicotinamide Cervical cancer Drug resistance
  • 相关文献

参考文献28

  • 1Canavan TP, DOSHI NR. Cervical cancer[J]. American Family Physi- cian, 2000, 61(5): 1369-1382.
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
  • 3Monk B J, Willmott LJ, Sumner DA. Anti-angiogenesis agents in meta- static or recurrent cervical cancer [J]. Gynecologic Oncology, 2010, 116(2): 181-186.
  • 4Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters[J]. Nature Reviews Cancer, 2002, 2(1): 48-58.
  • 5Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinic- al practice[J]. The Oncologist, 2003, 8(5): 411-424.
  • 6Fojo T, Bates S. Strategies for reversing drug resistance[J]. Oncogene, 2003, 22(47): 7512-7523.
  • 7Jones P, George A. The ABC transporter structure and mechanism: perspectives on recent research[J]. Cellular and Molecular Life Scienc- es, 2004, ~i1(6): 682-699.
  • 8刘玲,何玲,刘国卿.P糖蛋白与细胞凋亡及肿瘤多药耐药的关系[J].药学进展,2005,29(3):101-105. 被引量:15
  • 9Smoter M, Bodnar L, Duchnowska R, et al. The role of Tan protein in resistance to paclitaxel [J]. Cancer Chemotherapy and Pharmacology, 2011, 68(3): 553-557.
  • 10曾四元,梁美蓉,于晓红,魏宝秀,吴云燕,李隆玉.P-gp、GST-π、Topo-Ⅱ在宫颈癌组织中的表达及意义[J].实用癌症杂志,2008,23(3):256-259. 被引量:10

二级参考文献66

共引文献30

同被引文献21

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部